iNova Pharmaceuticals Executive and Leadership Team

Daniel Spira, the Chief Executive Officer at iNova Pharmaceuticals, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the development and commercialization of prescription medicines, the Chief Executive Officer ensures alignment between research initiatives and market demands across international territories. This leadership role involves constant collaboration with the Board to maintain competitive positioning within the global pharmaceutical landscape. By optimizing resource allocation, Daniel Spira drives sustainable growth and operational excellence across all regional divisions. The Chief Executive Officer monitors performance metrics to guarantee that the company meets rigorous quality standards while expanding the reach of consumer health products. Through decisive management, Spira secures the future trajectory of the firm, ensuring that the organization remains a leader in providing essential healthcare solutions to diverse populations throughout Asia, Australia, New Zealand, and Africa.

William Foo, the Group Chief Financial Officer at iNova Pharmaceuticals, governs the financial health and fiscal strategy of the entire organization. Directing capital allocation and investment planning, the Group Chief Financial Officer ensures that the company maintains the liquidity necessary to fund research and development for new prescription medicines. This leadership role involves managing complex financial reporting and risk assessment protocols to protect the interests of stakeholders. William Foo oversees the integration of financial data across international markets, providing the insights required for informed decision-making at the executive level. By implementing robust budgetary controls, the Group Chief Financial Officer supports the expansion of consumer health products into new territories. Foo maintains transparency in all fiscal operations, ensuring that the company adheres to global accounting standards. Through strategic financial planning, the Group Chief Financial Officer drives the long-term profitability and stability of the firm across its diverse operational footprint.

Paul Smith, the Chief Operating Officer at iNova Pharmaceuticals, manages the complex supply chain and manufacturing processes required to deliver pharmaceutical products to global markets. Coordinating with regional leads, the Chief Operating Officer optimizes internal workflows to enhance production efficiency and product availability. This role requires meticulous oversight of logistics and distribution networks to ensure that medicines reach patients across Asia, Australia, New Zealand, and Africa without interruption. Paul Smith implements scalable operational frameworks that support the company's mission of providing accessible healthcare solutions. By streamlining cross-functional communication, the Chief Operating Officer reduces overhead costs and improves service delivery speed. Smith maintains strict adherence to regulatory compliance standards, ensuring that every stage of the manufacturing cycle meets international safety benchmarks. Through rigorous process improvement, the Chief Operating Officer strengthens the foundation of the business, enabling consistent growth and reliable product supply across all operational regions.

Sacha Ernst, the President (Asia) at iNova Pharmaceuticals, leads all commercial activities and market expansion efforts throughout the Asian region. Overseeing the distribution of prescription medicines and consumer health products, the President (Asia) ensures that the company meets the unique healthcare needs of diverse Asian populations. This role involves building strategic partnerships with local distributors and healthcare providers to enhance product accessibility. Sacha Ernst monitors regional market dynamics to adjust sales strategies and maintain a competitive edge. By driving operational growth in key Asian markets, the President (Asia) contributes significantly to the overall revenue targets of the firm. Ernst coordinates with global leadership to ensure that regional initiatives align with the overarching corporate mission. Through proactive market management, the President (Asia) strengthens the company's footprint in the region, ensuring that patients receive reliable access to essential treatments and health products while maintaining high standards of service and quality.

Andrew Jenkin, the President, , Zealand (Canada, Australia) at iNova Pharmaceuticals, manages the commercial operations and strategic growth initiatives across the specified international territories. Overseeing the sales and marketing of prescription medicines, the President, , Zealand (Canada, Australia) ensures that the company maintains a strong market position in these regions. This role involves navigating complex regulatory environments and healthcare systems to deliver effective treatment solutions to patients. Andrew Jenkin directs local teams to optimize product distribution and enhance customer engagement. By identifying emerging market opportunities, the President, , Zealand (Canada, Australia) drives revenue growth and supports the company's commitment to global health. Jenkin collaborates with other regional leaders to share best practices and ensure consistent operational standards. Through focused leadership in these key markets, the President, , Zealand (Canada, Australia) secures the long-term success of the organization, ensuring that high-quality health products remain accessible to the populations served in these diverse geographic areas.

Johan Rempel, the President at iNova Pharmaceuticals, oversees the strategic development and execution of specialized business units focused on emerging therapeutic areas. Directing the integration of new product lines into the existing portfolio, the President ensures that the company remains at the forefront of pharmaceutical innovation. This role involves managing cross-functional teams to accelerate the time-to-market for new prescription medicines and consumer health products. Johan Rempel monitors global market trends to identify potential acquisitions or partnerships that enhance the company's capabilities. By fostering a culture of innovation, the President drives the development of advanced healthcare solutions that address unmet patient needs. Rempel collaborates with the executive team to refine the long-term growth strategy and ensure that the organization maintains its competitive advantage. Through visionary leadership, the President strengthens the company's position as a global provider of essential medicines, ensuring that the firm continues to deliver value to patients and stakeholders across all operational regions.

Omar Mahmoud, the Chief Marketing Officer, Commercial Quality, MENA at iNova Pharmaceuticals, architects the brand strategy and commercial quality standards for the Middle East and North Africa region. Overseeing the promotion of prescription medicines and consumer health products, the Chief Marketing Officer, Commercial Quality, MENA ensures that all marketing materials align with regional regulatory requirements and corporate quality benchmarks. This role involves analyzing market trends to identify growth opportunities within the MENA pharmaceutical sector. Omar Mahmoud collaborates with local teams to execute targeted campaigns that increase product awareness and market penetration. By maintaining high standards of commercial quality, the Chief Marketing Officer, Commercial Quality, MENA builds trust with healthcare providers and patients alike. Mahmoud drives the development of innovative engagement strategies that differentiate the company in a competitive landscape. Through focused regional leadership, the Chief Marketing Officer, Commercial Quality, MENA secures a strong market presence and supports the overall growth objectives of the organization.

Yee Goh, the Chief People Officer at iNova Pharmaceuticals, directs the human capital strategy and organizational development initiatives. Overseeing talent acquisition, employee engagement, and leadership training, the Chief People Officer ensures that the company attracts and retains the expertise necessary to innovate in the pharmaceutical industry. This role involves fostering a corporate culture that prioritizes performance, diversity, and professional growth across all international offices. Yee Goh implements comprehensive HR policies that support the well-being and productivity of the global workforce. By aligning personnel goals with the broader mission of the firm, the Chief People Officer drives organizational agility and operational success. Goh manages complex workforce planning to ensure that the company remains competitive in the global talent market. Through strategic human resources management, the Chief People Officer strengthens the internal capabilities of the organization, enabling the business to effectively deliver high-quality healthcare solutions to patients across Asia, Australia, New Zealand, and Africa.